Grand Pharmaceutical Group Limited

SEHK:512 Rapporto sulle azioni

Cap. di mercato: HK$15.5b

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Grand Pharmaceutical Group Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Grand Pharmaceutical Group ha un patrimonio netto totale di HK$15.9B e un debito totale di HK$4.5B, che porta il suo rapporto debito/patrimonio netto a 28.1%. Le sue attività totali e le sue passività totali sono rispettivamente HK$24.9B e HK$9.0B. L'EBIT di Grand Pharmaceutical Group è HK$3.0B rendendo il suo rapporto di copertura degli interessi 17.8. Ha liquidità e investimenti a breve termine pari a HK$2.3B.

Informazioni chiave

28.1%

Rapporto debito/patrimonio netto

HK$4.47b

Debito

Indice di copertura degli interessi17.8x
ContantiHK$2.32b
Patrimonio nettoHK$15.90b
Totale passivitàHK$9.00b
Totale attivitàHK$24.90b

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Grand Pharmaceutical Group (HKG:512) Is Paying Out A Larger Dividend Than Last Year

Jun 05
Grand Pharmaceutical Group (HKG:512) Is Paying Out A Larger Dividend Than Last Year

Market Participants Recognise Grand Pharmaceutical Group Limited's (HKG:512) Earnings

May 22
Market Participants Recognise Grand Pharmaceutical Group Limited's (HKG:512) Earnings

Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26

Apr 25
Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26

Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26

Mar 25
Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26

We Think Grand Pharmaceutical Group (HKG:512) Can Stay On Top Of Its Debt

Oct 20
We Think Grand Pharmaceutical Group (HKG:512) Can Stay On Top Of Its Debt

Here's Why We Think Grand Pharmaceutical Group (HKG:512) Is Well Worth Watching

Sep 26
Here's Why We Think Grand Pharmaceutical Group (HKG:512) Is Well Worth Watching

Grand Pharmaceutical Group's (HKG:512) Dividend Will Be Increased To HK$0.14

Jun 04
Grand Pharmaceutical Group's (HKG:512) Dividend Will Be Increased To HK$0.14

Is Grand Pharmaceutical Group (HKG:512) A Risky Investment?

May 05
Is Grand Pharmaceutical Group (HKG:512) A Risky Investment?

Grand Pharmaceutical Group (HKG:512) Seems To Use Debt Quite Sensibly

Nov 21
Grand Pharmaceutical Group (HKG:512) Seems To Use Debt Quite Sensibly

Is Grand Pharmaceutical Group Limited (HKG:512) Trading At A 43% Discount?

Sep 05
Is Grand Pharmaceutical Group Limited (HKG:512) Trading At A 43% Discount?

Grand Pharmaceutical Group (HKG:512) Seems To Use Debt Quite Sensibly

Aug 16
Grand Pharmaceutical Group (HKG:512) Seems To Use Debt Quite Sensibly

Here's Why We Think Grand Pharmaceutical Group (HKG:512) Is Well Worth Watching

Jul 28
Here's Why We Think Grand Pharmaceutical Group (HKG:512) Is Well Worth Watching

Grand Pharmaceutical Group's (HKG:512) Dividend Will Be HK$0.11

May 29
Grand Pharmaceutical Group's (HKG:512) Dividend Will Be HK$0.11

Is Grand Pharmaceutical Group Limited (HKG:512) Trading At A 45% Discount?

Apr 08
Is Grand Pharmaceutical Group Limited (HKG:512) Trading At A 45% Discount?

Grand Pharmaceutical Group (HKG:512) Has A Rock Solid Balance Sheet

Mar 22
Grand Pharmaceutical Group (HKG:512) Has A Rock Solid Balance Sheet

If You Like EPS Growth Then Check Out Grand Pharmaceutical Group (HKG:512) Before It's Too Late

Jan 24
If You Like EPS Growth Then Check Out Grand Pharmaceutical Group (HKG:512) Before It's Too Late

These 4 Measures Indicate That Grand Pharmaceutical Group (HKG:512) Is Using Debt Safely

Dec 13
These 4 Measures Indicate That Grand Pharmaceutical Group (HKG:512) Is Using Debt Safely

Grand Pharmaceutical Group Limited's (HKG:512) Intrinsic Value Is Potentially 45% Above Its Share Price

Nov 27
Grand Pharmaceutical Group Limited's (HKG:512) Intrinsic Value Is Potentially 45% Above Its Share Price

With EPS Growth And More, China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Is Interesting

Oct 25
With EPS Growth And More, China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Is Interesting

China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Seems To Use Debt Rather Sparingly

Sep 01
China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Seems To Use Debt Rather Sparingly

Do China Grand Pharmaceutical and Healthcare Holdings's (HKG:512) Earnings Warrant Your Attention?

Jul 12
Do China Grand Pharmaceutical and Healthcare Holdings's (HKG:512) Earnings Warrant Your Attention?

We Think China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Can Stay On Top Of Its Debt

Apr 26
We Think China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Can Stay On Top Of Its Debt

Calculating The Fair Value Of China Grand Pharmaceutical and Healthcare Holdings Limited (HKG:512)

Apr 08
Calculating The Fair Value Of China Grand Pharmaceutical and Healthcare Holdings Limited (HKG:512)

Here's Why We Think China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Is Well Worth Watching

Mar 24
Here's Why We Think China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Is Well Worth Watching

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( HK$8.2B ) di 512 superano le sue passività a breve termine ( HK$6.4B ).

Passività a lungo termine: Le attività a breve termine di 512 ( HK$8.2B ) superano le sue passività a lungo termine ( HK$2.6B ).


Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: Il rapporto debito netto/patrimonio netto ( 13.5% ) di 512 è considerato soddisfacente.

Riduzione del debito: Il rapporto debito/patrimonio netto di 512 si è ridotto da 29.4% a 28.1% negli ultimi 5 anni.

Copertura del debito: Il debito di 512 è ben coperto dal flusso di cassa operativo ( 54.3% ).

Copertura degli interessi: I pagamenti degli interessi sul debito di 512 sono ben coperti dall'EBIT ( 17.8 x copertura).


Bilancio


Scoprire le aziende sane